Jwa68 Posted - 22 minutes ago

$GANX $COYA This is well done and spot on frankly. I agree completely on his risk versus reward investment thesis, especially in light of the recent retracement in price and very positive SAD data. Soon approaching MAD data and recent high quality management additions are also encouraging. Throw the recent insider buying on top of all of it. Do your own dd as always.

vo2macs Posted - 1 hour ago

$COYA Higher highs and lows. Time for the next step up.

RealAvidTrader Posted - 2 hours ago

$GANX $COYA Why is Billionaire David Einhorn Buying This Stock? https://youtu.be/A8oSwYDhldU

microcapspeculator Posted - 4 hours ago

$COYA Good Seeking Alpha article out today. Why Coya Is A Smart Speculative Buy For Neurodegenerative Diseases | Seeking Alpha https://seekingalpha.com/article/4687901-why-coya-therapeutics-is-a-smart-speculative-buy-for-neurodegenerative-diseases

Will2ride1 Posted - 11 hours ago

$COYA

EmotionlessRobot Posted - 18 hours ago

$COYA https://www.sciencealert.com/brain-autopsies-reveal-a-potential-new-culprit-behind-alzheimers-disease "some microglia respond too strongly and may cause inflammation that contributes to the death of brain cells." https://academic.oup.com/brain/article/140/3/826/2726614 https://pubmed.ncbi.nlm.nih.gov/7536800/

Will2ride1 Posted - 04/30/24

$COYA very nice 📈

Jwa68 Posted - 04/30/24

$COYA Nice close.

microcapspeculator Posted - 04/30/24

$COYA Here is recent Chardan report where they raised target to $14. Always interesting when a stock moves opposite the general market. Coya Therapeutics (COYA): Chardan PT to $14 on Advancement of Coya 302 for Multiple Indications in 24 https://coyatherapeutics.wordpress.com/2024/03/20/coya-therapeutics-coya-chardan-pt-to-14-on-advancement-of-coya-302-for-multiple-indications-in-24/

microcapspeculator Posted - 04/30/24

$COYA Rodman and Renshaw initiates coverage with price target $18. Coya Therapeutics (COYA): Rodman and Renshaw PT $18 Tackling Neuroinflammation April 30th,2024 https://coyatherapeutics.wordpress.com/2024/04/30/coya-therapeutics-coya-rodman-and-renshaw-pt-18-tackling-neuroinflammation-april-30th2024/

Jwa68 Posted - 04/30/24

$COYA Rodman and Renshaw initiates coverage of Coya with a Buy and $18 target.

Jwa68 Posted - 04/29/24

$COYA https://www.biospace.com/article/5-mid-stage-als-drugs-to-watch-/

microcapspeculator Posted - 04/29/24

$COYA 5 Mid-Stage ALS Drugs to Watch Coya Therapeutics’ lead program, COYA 302, is a regulatory T cells (Treg)-targeted therapy in development for ALS, frontotemporal dementia, Parkinson’s disease and Alzheimer’s disease. It is currently in Phase II trials for ALS. https://www.biospace.com/article/5-mid-stage-als-drugs-to-watch-/

microcapspeculator Posted - 04/27/24

$COYA Coya Therapeutics CEO Discusses Recent Data Discovery from a Study of Coya 302, a Potential Treatment for ALS https://www.pharmexec.com/view/coya-therapeutics-ceo-discusses-recent-data-discovery-from-a-study-of-coya-302-a-potential-treatment-for-als PE: Coya presented data from a study for the treatment of ALS. Berman: First, Coya 302 is a combination of two different drugs. It's a low-dose IL-2, to enhance regulatory T cells, and CTLA-4. We ran a proof of concept study for patients who were progressing relatively quickly, prior to treatment. We measured safety, tolerability, biomarkers, and the efficacy, which is the ALS FRS scale. That's the typical scale that is measured in ALS patients. At six months, we showed that instead of declining six or seven or eight points, which you would typically see, there was no decline in all four of our patients. Then at 12 months, where you would typically see a decline of maybe 14 points on the scale, there was only a very minor decline of 1.5 points. Correlating with the biomarkers, we're doing a larger trial, which is in process and we're filing the IND very soon.

microcapspeculator Posted - 04/27/24

$COYA Coya Therapeutics CEO Discusses Next Steps Amid Positive Results from Coya 302 Trial for ALS Treatment https://www.pharmexec.com/view/coya-therapeutics-ceo-discusses-next-steps-amid-positive-results-from-coya-302-trial-for-als-treatment PE: After this trial, what are next step Berman: Now, we have discovered through multiple trials that free radicals in particular, is heightened in patients. In fact, it is strongly correlate of of survival. One could actually measure the patient's blood and get a level of 4HNE in the blood. I could predict with a high degree of certainty if the patient will be alive or dead within 24 months. We've been able to do a longitudinal study, we did it initially in 50 patients. Now, we've done it in 100 patients and data will be presented there as well. We're going to work with the FDA on this in terms of future breakthrough designation. Our thesis is that, yes, it's a predictive biomarker survival, but it's also a marker that if you can lower and you can show that you're lowering the surrogate marker, it would be used as evidence that the treatment is efficacious and working.

microcapspeculator Posted - 04/27/24

$COYA Future pipeline. Coya Therapeutics CEO Discusses Company's Treatment Pipeline https://www.pharmexec.com/view/coya-therapeutics-ceo-discusses-company-s-treatment-pipeline PE: Is there anything else in Coya’s pipeline that is the works that you would like to speak about? Berman: Going back to 302, it's a pipeline. We call it a pipeline in a product. Imagine now being able to control many different conditions with that one combination approach. In addition to that, we're developing combination approaches with the low dose IL2 portion. We can now take IL2 and combine it with TNF alpha drugs, GMCSF, or other compounds that may be synergistic. It opens up a unique way to now have opportunities to slow inflammation, not necessarily just with the CTLA4 component or the abatacept, but in other capacities as well. That's very interesting to companies. Then of course, we have our exosomes, which we don't talk too much about, but it's a type of vesicle in the cell

microcapspeculator Posted - 04/27/24

$COYA If the Gates Foundation trial repeats previous data and shows improved cognition what will this be worth? They probably have a good indication since the trial should be about finished and reads out in next few months. Howard Berman Discusses Potential Indications for Coya 302 https://www.pharmexec.com/view/howard-berman-discusses-potential-indications-for-coya-302 PE: Regarding the other intended indications for Coya 302, can you elaborate on any data found from clinical trials focused on these areas? Berman: We're also reading out data in Alzheimer's. A trial was run and data was published last year with one of the components of Coya 302. It's the low dose IL2 portion by itself. Remarkably, what we saw, and we didn't anticipate this, was that the patients actually improved their cognition and their blood biomarkers were improved, everything that you would anticipate. We went and showed this to the Gates Foundation and the Alzheimer's Association and they agreed to fund a randomized double blind trial, and that's reading out in the next few months.

briefingcom Posted - 04/26/24

$COYA: Coya Therapeutics presents updated ALS biomarker data at the 2nd Annual Johnson Center Symposium https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240426081719COYA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Will2ride1 Posted - 04/26/24

$COYA

Finanz Posted - 04/26/24

$COYA The biotechs with good news are really doing great this year.

microcapspeculator Posted - 04/26/24

$COYA The data on how well Coya-302 works on this biomarker is in all their data. Just need to file the IND next on the Phase 2 ALS study. Serum 4-HNE Receiver Operating Curve (ROC) Analysis demonstrates a 100% sensitivity for survival threshold of 21 months, indicating that it is a highly promising candidate biomarker in ALS and an independent monitor of clinical status for the upcoming COYA 302 Ph. 2 clinical trial

Stock_Titan Posted - 04/26/24

$COYA Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium https://www.stocktitan.net/news/COYA/coya-therapeutics-presents-updated-als-biomarker-data-at-the-2nd-c35ehes30hmj.html

RealAvidTrader Posted - 04/25/24

$COYA $GANX $WULF

microcapspeculator Posted - 04/25/24

$COYA The data can all be found linked in this press release. Its pretty significant what they are saying about these biomarkers. Go through the presentation. Fast track and breakthrough designation. Coya Therapeutics - Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Presents-ALS-Biomarker-Data-at-Society-of-Neuroimmune-Pharmacology-Conference/default.aspx

microcapspeculator Posted - 04/25/24

$COYA This biomarker data is very significant.Sets stage for successful ALS trial. They know they can lower. https://www.pharmexec.com/view/ai-parkinson-treatments-mattias-alder Now, we've done it in 100 patients and data will be presented there as well. It's been validated in our hands. We're going to work with the FDA on this in terms of future breakthrough designation. Our thesis is that, yes, it's a predictive biomarker survival, but it's also a marker that if you can lower and you can show that you're lowering the surrogate marker, it would be used as evidence that the treatment is efficacious and working.

Jwa68 Posted - 04/24/24

$GANX Good listen. I agree with his comments on Small bios being attractive quick ways to rebuild major pharma pipelines. This and $COYA remain my two favorite small names. https://www.linkedin.com/posts/lou-basenese-174821128_fed-ai-gold-activity-7188873910388502530-q8KP?utm_source=share&utm_medium=member_android

microcapspeculator Posted - 04/24/24

$COYA The Alzheimer's study gets zero valuation here and it should be completed at any time and reads out this summer. Looking at the original 8 patient trial the data looks very good. This Gates funded trial is longer and one cohort doubled the doses. Does anyone else think they went back and did more preclinical testing to improve the results in this trial? I actually discussed this with the company. They are much smarter than I am. Lol.

EmotionlessRobot Posted - 04/24/24

$COYA

microcapspeculator Posted - 04/24/24

$COYA Crazy that the world's top ALS company sells for around $100m market cap and has $40m in cash. I suspect institutions will start to eat up the float with IND filing and Gates sponsored ALS data coming up.

microcapspeculator Posted - 04/24/24

$COYA Leaders in ALS research. Validating A Better ALS Biomarker With Coya's Fred Grossman A conversation with Fred Grossman, DO, FAPA, president and chief medical officer, Coya Therapeutics https://www.clinicalleader.com/doc/validating-a-better-als-biomarker-with-coya-s-fred-grossman-0001 To that end, Coya will apply for Fast Track designation concurrently with our initial IND submission. Pending availability and review of topline results from the Phase 2 study, Coya will apply for Breakthrough designation. Coya also will pursue conversations with other health authorities as part of our overall global regulatory strategy.